PDF

Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Full Year 2017 Financial Results

LEXINGTON, Mass., March 22, 2018 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with inflammatory diseases, will issue financial results for the year ended December 31, 2017, on Thursday, March 29, 2018, prior to the market open.

Aldeyra will hold a conference call on Thursday, March 29, 2018, at 8:00 a.m. EDT to discuss the results.  The dial-in numbers are 1-877-266-8979 for domestic callers and 1-412-317-5231 for international callers.  A live webcast of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at www.aldeyra.com

After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year.

About Aldeyra Therapeutics
Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with inflammatory diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. Aldeyra is leveraging its experience in ocular inflammation to develop other product candidates for systemic inflammatory disease. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.

Corporate Contact: 
Stephen Tulipano 
Aldeyra Therapeutics, Inc. 
Tel: +1 781-761-4904 ext. 205  
stulipano@aldeyra.com

Investor Contact: 
Chris Brinzey 
Westwicke Partners 
Tel: 339-970-2843 
Chris.brinzey@westwicke.com

Media Contact:
Cammy Duong 
MacDougall Biomedical Communications  
781-591-3443 
cduong@macbiocom.com

 

Cision View original content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-schedules-webcast-and-conference-call-to-provide-full-year-2017-financial-results-300618473.html

SOURCE Aldeyra Therapeutics, Inc.

News Provided by Acquire Media